NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) today announced the release of a white paper titled “StereoCED™ - A Scalable Platform for CNS Drug Delivery,” which examines how the company’s investigational platform aims to overcome key barriers in the commercial delivery of brain therapeutics. The white paper is available from the Scientific Resources section of www.nmtc1.com.
The white paper highlights that advances in cell and gene therapies, biologics, and other central nervous system (CNS) therapeutics are increasing demand for efficient, reproducible methods of delivering therapies directly to the brain. While convection-enhanced delivery (CED) has demonstrated the ability to bypass the blood-brain barrier and achieve targeted drug distribution, current approaches may present challenges as therapies move toward broader commercial use.
The StereoCED™ drug delivery platform is being designed to address these challenges by leveraging robotic stereotactic systems already established in neurosurgical operating rooms. Rather than requiring specialized workflows and lengthy sequential infusions, the platform is designed to support simultaneous, multi-trajectory intracranial drug delivery through a streamlined robotic workflow. This approach has the potential to significantly reduce procedure time while enabling reproducible, scalable therapeutic delivery.
“Brain-delivered therapeutics are approaching an important inflection point,” said Dave Rosa, President and Chief Executive Officer of NeuroOne. “As these therapies move toward commercialization, certain intracranial infusion procedures lasting 8 to 12 hours may become a significant bottleneck to commercial adoption. We believe healthcare systems will need solutions that leverage established neurosurgical workflows, significantly reduce procedure time, and support scalable delivery across hospitals. StereoCED™ is being designed with those needs in mind, and we look forward to device availability for research and investigational clinical studies by fiscal year-end.”
The StereoCED™ platform is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration for commercialization. The white paper underscores that the platform’s design could help address the scalability of CNS drug delivery, which is critical as more therapies approach market readiness. By integrating with existing robotic systems, StereoCED™ aims to lower the barrier for hospitals to adopt advanced brain delivery procedures without requiring entirely new infrastructure.
NeuroOne, a medical technology company focused on improving surgical care for neurological disorders, markets four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
